|Dr. David J. Mazzo||Pres, CEO & Director||972.93k||N/A||1957|
|Mr. Todd C. Girolamo M.B.A., J.D., Esq.||Chief Legal Officer, Sr. VP of Corp. Devel. & Corp. Sec.||456.39k||N/A||1966|
|Dr. William K. Sietsema Ph.D.||VP of Global Regulatory Affairs||350.55k||N/A||1956|
|Mr. James Nisco||VP of Fin. & Treasury||N/A||N/A||N/A|
|Mr. Gregory S. Berkin||VP of Information Technology & Cyber security and Chief Information Officer||N/A||N/A||N/A|
|Mr. John D. Menditto||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Eric Powers||Director of Communications and Marketing||N/A||N/A||N/A|
|Ms. Gail Holler||VP of HR||N/A||N/A||1959|
|Dr. Kristen K. Buck M.D.||Exec. VP of R&D and Chief Medical Officer||N/A||N/A||N/A|
|Dr. Ian Zhang Ph.D., MBA||Pres of NeoStem (China), Inc and Managing Director of NeoStem (China), Inc||N/A||N/A||1965|
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; OLOGO, a regenerative medicine advanced therapy for treating no-option refractory disabling angina; CLBS16 that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Caladrius Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.